SEC Form 4 · accession 0001209191-18-004651
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacques Dumas
Officer — Chief ScientificOfficer
Period of report
Jan 17, 2018
Accepted (ET)
Jan 19, 2018 · 7:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Jan 17, 2018 | A | 40,000 | A | — | — | Common Stock | 40,000 | 40,000 | D |
| Employee Stock Option (Right to Buy)F3 | $6.24 | Jan 17, 2018 | A | 140,000 | A | — | Jan 16, 2028 | Common Stock | 140,000 | 140,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration.
- F2These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on January 31, 2021.
- F3Vests as to 6.25% of the shares on 4/17/2018 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/17/2022.